BUZZ-IDEAYA Biosciences rises as early-stage cancer trial starts

** Shares of biotech firm IDEAYA Biosciences IDYA.O rise 1.3% to $33.12 premarket

** Co says it enrolled the first patient in an early-stage trial of IDE574, an experimental pill for solid tumors, or cancers that form lumps in organs such as the breast, lung, prostate and colon

** Drug blocks two proteins, KAT6 and KAT7, which help cancer cells survive; lab studies showed longer-lasting tumor growth slowdown than drugs targeting one protein alone - IDYA

** Early-stage study is testing safety and how the body processes the drug when used alone, co says

** Adds it will study IDE574 in some breast cancer patients who stop responding to hormone treatments due to genetic changes

** Says it may also test the drug with other treatments from its own pipeline

** Co expects to share more data at a cancer research meeting later this year

** As of last close, stock down ~5% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))